This Article Full Text Full Text (PDF) All Versions of this Article: 39/8/2336    most recent STROKEAHA.107.507111v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dani, K. A. Articles by Muir, K. W. Search for Related Content PubMed PubMed Citation Articles by Dani, K. A. Articles by Muir, K. W. Related Collections Other Ethics and Policy CT and MRI Acute Stroke Syndromes Computerized tomography and Magnetic Resonance Imaging

(Stroke. 2008;39:2336.)
© 2008 American Heart Association, Inc.

Original Contributions

Brain Lesion Volume and Capacity for Consent in Stroke Trials

Potential Regulatory Barriers to the Use of Surrogate Markers

Krishna A. Dani, MRCP; Michael T. McCormick, MRCP Keith W. Muir, MD, FRCP

From the Division of Clinical Neurosciences, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland, UK.

Correspondence to Dr Keith Muir, Division of Clinical Neurosciences, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow G51 4TF, Scotland, UK. E-mail k.muir{at}clinmed.gla.ac.uk

Background and Purpose— European directives and legislation in some countries forbid inclusion of subjects incapable of consent in research if recruitment of patients capable of consent will yield similar results. We compared brain lesion volumes in stroke patients deemed to have capacity to consent with those defined as incapacitated.

Methods— Data were obtained from 3 trials recruiting patients primarily with cortical stroke syndromes. Patients were recruited within 24 hours of onset and used MRI based selection or outcome criteria. Method of recruitment was recorded with stroke severity, age, and brain lesion volumes on Diffusion Weighted Imaging.

Results— Of the 56 subjects included, 38 (68%) were recruited by assent and 18 (32%) by consent. The assent group had a median lesion volume of 18.35 cubic centimetres (cc) (interquartile range [IQR] 8.27–110.31 cc), compared to 2.79 cc (IQR 1.31–12.33 cc) when patients consented (P=0.0004). Lesions were smaller than 5 cc in 7/38 (18%) in the assent group and 11/18 (61%) in the consent group (P=0.0024). There was good correlation between neurological deficit by NIH stroke scale score and lesion volume (r=0.584, P<0.0001). Logistic regression demonstrated NIHSS or lesion volume predicted capacity to consent.

Conclusions— Patients with acute stroke who retain capacity to consent have significantly smaller infarct volumes than those incapable of consent, and these are frequently below the limits where measurement error significantly compromises valid use of volumetric end points. Only a small proportion of patients with capacity to consent would be eligible for, and contribute usefully to, most acute stroke trial protocols.

Key Words: clinical trials • informed consent • magnetic resonance imaging • ethics

This article has been cited by other articles:

				S. E. Kasner, A. Del Giudice, S. Rosenberg, M. Sheen, J. M. Luciano, B. L. Cucchiara, S. R. Messe, L. H. Sansing, and J. M. Baren Who will participate in acute stroke trials? Neurology, May 12, 2009; 72(19): 1682 - 1688. [Abstract] [Full Text] [PDF]